obesity

Global obesity drugs sales could top $44bn in 2030, says Bloomberg Intelligence
Global obesity drugs sales could top $44bn in 2030, says Bloomberg Intelligence
Biopharma Reporter
obesity
weight loss
Novo Nordisk
Eli Lilly
Pfizer
Amgen
Flag link:
Lilly steps up its oral obesity push
Lilly steps up its oral obesity push
EP Vantage
Eli Lilly
obesity
GLP-1 agonist
orforglipron
Flag link:
Next-gen Lilly obesity drug slashes weight in Innovent study—but is it enough to rival Mounjaro?
Next-gen Lilly obesity drug slashes weight in Innovent study—but is it enough to rival Mounjaro?
Fierce Biotech
Innovent
Eli Lilly
obesity
mazdutide
clinical trials
Flag link:
Zealand, Boehringer's drug meets main weight-loss goal in mid-stage trial
Zealand, Boehringer's drug meets main weight-loss goal in mid-stage trial
BioSpace
Boehringer Ingelheim
Zealand Pharma
obesity
clinical trials
BI 456906
Flag link:
‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs
‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs
Stat
side effects
Ozempic
Wegovy
Mounjaro
Novo Nordisk
Eli Lilly
obesity
Flag link:
Amid high demand, Novo Nordisk temporarily throttles US supply of low-dose Wegovy
Amid high demand, Novo Nordisk temporarily throttles US supply of low-dose Wegovy
Fierce Pharma
Novo Nordisk
Wegovy
obesity
Flag link:
Quitting Lilly's obesity drug tirzepatide may be difficult for many patients, exec says
Quitting Lilly's obesity drug tirzepatide may be difficult for many patients, exec says
Fierce Pharma
Eli Lilly
obesity
tirzepatide
patients
Flag link:
Lilly drug Mounjaro succeeds in second weight loss study
Lilly drug Mounjaro succeeds in second weight loss study
BioPharma Dive
Eli Lilly
obesity
Mounjaro
clinical trials
Flag link:
In heavyweight obesity fight, Eli Lilly launches Mounjaro head-to-head trial against Novo Nordisk's Wegovy
In heavyweight obesity fight, Eli Lilly launches Mounjaro head-to-head trial against Novo Nordisk's Wegovy
Fierce Pharma
Eli Lilly
clinical trials
obesity
Mounjaro
Novo Nordisk
Wegovy
Flag link:
Novo’s latest deal targets cell therapy for diabetes, obesity
Novo’s latest deal targets cell therapy for diabetes, obesity
BioPharma Dive
Novo Nordisk
cell therapy
diabetes
obesity
Aspect Biosystems
Flag link:
Diabesity drugs and their free ‘contract sales force’
Diabesity drugs and their free ‘contract sales force’
Medical Marketing and Media
Novo Nordisk
Eli Lilly
diabetes
obesity
telehealth
social media
Mounjaro
Wegovy
Flag link:
Boehringer signals intent in obesity
Boehringer signals intent in obesity
EP Vantage
Boehringer Ingelheim
Zealand Pharma
obesity
clinical trials
BI 456906
Flag link:
Viking sets ships toward phase 2 after obesity med passes early test
Viking sets ships toward phase 2 after obesity med passes early test
Fierce Biotech
Viking Therapeutics
obesity
clinical trials
VK2735
Flag link:
The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win
The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win
Investors Business Daily
Novo Nordisk
Ozempic
diabetes
obesity
Flag link:
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
CP Wire
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Flag link:
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Flag link:
Altimmune's obesity drug throws up safety concerns, shares plunge
Altimmune's obesity drug throws up safety concerns, shares plunge
Yahoo/Reuters
Altimmune
obesity
clinical trials
Flag link:
Covering new weight loss drugs could strain Medicare, policy experts warn
Covering new weight loss drugs could strain Medicare, policy experts warn
Stat
obesity
Medicare
Wegovy
Novo Nordisk
Flag link:
Altimmune aims to build Momentum in obesity
Altimmune aims to build Momentum in obesity
EP Vantage
Altimmune
incretin pemvidutide
obesity
Flag link:
Eli Lilly's diabetes drug Mounjaro back in stock amid heightened obesity interest
Eli Lilly's diabetes drug Mounjaro back in stock amid heightened obesity interest
Fierce Pharma
Eli Lilly
Mounjaro
diabetes
obesity
drug shortages
Flag link:

Pages